• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

MPES-R:R 中的多参数证据综合法用于生存外推——教程。

MPES-R: Multi-Parameter Evidence Synthesis in R for Survival Extrapolation-A Tutorial.

机构信息

School of Medicine and Population Health, Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, UK.

Delta Hat, Nottingham, UK.

出版信息

Pharmacoeconomics. 2024 Dec;42(12):1317-1327. doi: 10.1007/s40273-024-01425-4. Epub 2024 Aug 29.

DOI:10.1007/s40273-024-01425-4
PMID:39207595
Abstract

Survival extrapolation often plays an important role in health technology assessment (HTA), and there are a range of different approaches available. Approaches that can leverage external evidence (i.e. data or information collected outside the main data source of interest) may be helpful, given the extent of uncertainty often present when determining a suitable survival extrapolation. One of these methods is the multi-parameter evidence synthesis (MPES) approach, first proposed for use in HTA by Guyot et al., and more recently by Jackson. While MPES has potential benefits over conventional extrapolation approaches (such as simple or flexible parametric models), it is more computationally complex and requires use of specialist software. This tutorial presents an introduction to MPES for HTA, alongside a user-friendly, publicly available operationalisation of Guyot's original MPES that can be executed using the statistical software package R. Through two case studies, both Guyot's and Jackson's MPES approaches are explored, along with sensitivity analyses relevant to HTA. Finally, the discussion section of the tutorial details important considerations for analysts considering use of an MPES approach, along with potential further developments. MPES has not been used often in HTA, and so there are limited examples of how it has been used and perceived. However, this tutorial may aid future research efforts exploring the use of MPES further.

摘要

生存外推在卫生技术评估(HTA)中经常起着重要作用,并且有多种不同的方法可供选择。鉴于在确定合适的生存外推时常常存在很大的不确定性,因此利用外部证据(即从主要感兴趣数据源之外收集的数据或信息)的方法可能会有所帮助。其中一种方法是多参数证据综合(MPES)方法,该方法最初由 Guyot 等人提出用于 HTA,最近由 Jackson 提出。虽然 MPES 相对于传统的外推方法(如简单或灵活的参数模型)具有潜在的优势,但它的计算更为复杂,需要使用专业软件。本教程介绍了用于 HTA 的 MPES,并提供了 Guyot 最初的 MPES 的用户友好型、公开可用的操作化版本,可使用统计软件包 R 执行该操作化版本。通过两个案例研究,探索了 Guyot 和 Jackson 的 MPES 方法以及与 HTA 相关的敏感性分析。最后,本教程的讨论部分详细介绍了考虑使用 MPES 方法的分析师需要考虑的重要问题,以及可能的进一步发展。MPES 在 HTA 中尚未得到广泛应用,因此关于其使用和看法的例子有限。但是,本教程可能有助于进一步探索使用 MPES 的未来研究工作。

相似文献

1
MPES-R: Multi-Parameter Evidence Synthesis in R for Survival Extrapolation-A Tutorial.MPES-R:R 中的多参数证据综合法用于生存外推——教程。
Pharmacoeconomics. 2024 Dec;42(12):1317-1327. doi: 10.1007/s40273-024-01425-4. Epub 2024 Aug 29.
2
Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up.在两项晚期非小细胞肺癌(NSCLC)纳武单抗试验中,利用先进的灵活建模方法从早期随访数据进行生存外推并延长随访时间。
Med Decis Making. 2023 Jan;43(1):91-109. doi: 10.1177/0272989X221132257. Epub 2022 Oct 19.
3
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
4
Survival Extrapolation Incorporating General Population Mortality Using Excess Hazard and Cure Models: A Tutorial.利用超额风险和治愈模型纳入一般人群死亡率的生存外推:教程。
Med Decis Making. 2023 Aug;43(6):737-748. doi: 10.1177/0272989X231184247. Epub 2023 Jul 13.
5
Blended Survival Curves: A New Approach to Extrapolation for Time-to-Event Outcomes from Clinical Trials in Health Technology Assessment.混合生存曲线:一种从健康技术评估临床试验中推断事件时间结局的新方法。
Med Decis Making. 2023 Apr;43(3):299-310. doi: 10.1177/0272989X221134545. Epub 2022 Oct 31.
6
A Systematic Review of Methods to Incorporate External Evidence into Trial-Based Survival Extrapolations for Health Technology Assessment.系统评价将外部证据纳入基于试验的生存外推法用于卫生技术评估的方法。
Med Decis Making. 2023 Jul;43(5):610-620. doi: 10.1177/0272989X231168618. Epub 2023 Apr 26.
7
A Multistate Model Incorporating Relative Survival Extrapolation and Mixed Time Scales for Health Technology Assessment.一种用于卫生技术评估的、纳入相对生存外推法和混合时间尺度的多状态模型。
Pharmacoeconomics. 2025 Mar;43(3):297-310. doi: 10.1007/s40273-024-01457-w. Epub 2024 Nov 25.
8
Evidence generation throughout paediatric medicines life cycle: findings from collaborative work between European Medicines Agency (EMA) and EUnetHTA on use of extrapolation.儿科药物全生命周期的证据生成:欧洲药品管理局(EMA)与欧盟卫生技术评估网络(EUnetHTA)关于外推法使用的合作成果
Br J Pharmacol. 2025 Feb;182(3):484-494. doi: 10.1111/bph.17396. Epub 2024 Nov 22.
9
survextrap: a package for flexible and transparent survival extrapolation.survextrap:一个用于灵活透明生存外推的软件包。
BMC Med Res Methodol. 2023 Nov 29;23(1):282. doi: 10.1186/s12874-023-02094-1.
10
When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.多少证据才算足够?——运用系统决策分析和信息价值分析来确定是否需要更多证据。
Z Evid Fortbild Qual Gesundhwes. 2013;107(9-10):575-84. doi: 10.1016/j.zefq.2013.10.020. Epub 2013 Nov 12.

引用本文的文献

1
Structured Expert Elicitation to Inform Long-Term Survival Extrapolations in Advanced Renal Cell Carcinoma.结构化专家咨询法为晚期肾细胞癌长期生存推断提供信息
Appl Health Econ Health Policy. 2025 Aug 27. doi: 10.1007/s40258-025-01000-8.
2
An Evaluation of an Algorithm for the Selection of Flexible Survival Models for Cancer Immunotherapies: Pass or Fail?一种用于选择癌症免疫疗法中灵活生存模型的算法评估:通过还是失败?
Pharmacoeconomics. 2024 Dec;42(12):1395-1412. doi: 10.1007/s40273-024-01429-0. Epub 2024 Sep 20.

本文引用的文献

1
survextrap: a package for flexible and transparent survival extrapolation.survextrap:一个用于灵活透明生存外推的软件包。
BMC Med Res Methodol. 2023 Nov 29;23(1):282. doi: 10.1186/s12874-023-02094-1.
2
The Role of Expert Opinion in Projecting Long-Term Survival Outcomes Beyond the Horizon of a Clinical Trial.专家意见在预测临床试验范围以外的长期生存结果中的作用。
Adv Ther. 2023 Jun;40(6):2741-2751. doi: 10.1007/s12325-023-02503-3. Epub 2023 Apr 18.
3
Direct Incorporation of Expert Opinion into Parametric Survival Models to Inform Survival Extrapolation.
将专家意见直接纳入参数生存模型,以提供生存外推信息。
Med Decis Making. 2023 Apr;43(3):325-336. doi: 10.1177/0272989X221150212. Epub 2023 Jan 16.
4
Is the assumption of waning of treatment effect applied consistently across NICE technology appraisals? A case-study focusing on disease-modifying therapies for treatment of multiple sclerosis.是否在 NICE 技术评估中一致应用治疗效果减弱的假设?以治疗多发性硬化症的疾病修正疗法为重点的案例研究。
Int J Technol Assess Health Care. 2022 Dec 13;38(1):e83. doi: 10.1017/S0266462322003269.
5
Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up.在两项晚期非小细胞肺癌(NSCLC)纳武单抗试验中,利用先进的灵活建模方法从早期随访数据进行生存外推并延长随访时间。
Med Decis Making. 2023 Jan;43(1):91-109. doi: 10.1177/0272989X221132257. Epub 2022 Oct 19.
6
Structured expert elicitation to inform long-term survival extrapolations using alternative parametric distributions: a case study of CAR T therapy for relapsed/ refractory multiple myeloma.采用替代参数分布的结构化专家 elicitation 来推断长期生存外推:以复发/难治性多发性骨髓瘤的 CAR T 治疗为例的案例研究。
BMC Med Res Methodol. 2022 Oct 15;22(1):272. doi: 10.1186/s12874-022-01745-z.
7
Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43 895 trials and 5 685 738 individuals across 989 unique drugs and 286 conditions in England.比较临床试验人群代表性与真实世界人群:一项涵盖英国989种独特药物和286种病症的43895项试验及5685738名个体的外部有效性分析。
Lancet Healthy Longev. 2022 Oct;3(10):e674-e689. doi: 10.1016/S2666-7568(22)00186-6. Epub 2022 Sep 20.
8
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC.KEYNOTE-010 研究:帕博利珠单抗对比多西他赛用于治疗既往接受过治疗、PD-L1 阳性的晚期 NSCLC 的 5 年生存更新。
J Thorac Oncol. 2021 Oct;16(10):1718-1732. doi: 10.1016/j.jtho.2021.05.001. Epub 2021 May 26.
9
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.帕博利珠单抗对比化疗用于 PD-L1 肿瘤比例分数≥50%的转移性非小细胞肺癌的 5 年结果。
J Clin Oncol. 2021 Jul 20;39(21):2339-2349. doi: 10.1200/JCO.21.00174. Epub 2021 Apr 19.
10
An Evaluation of Survival Curve Extrapolation Techniques Using Long-Term Observational Cancer Data.利用长期观测性癌症数据评估生存曲线外推技术。
Med Decis Making. 2019 Nov;39(8):926-938. doi: 10.1177/0272989X19875950. Epub 2019 Oct 20.